Know Cancer

forgot password

A Phase 3 Randomized Trial of Concurrent Cisplatin & Radiotherapy With Or Without ONCOVEXGM-CSF In Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck

Phase 3
18 Years
Not Enrolling

Thank you

Trial Information

A Phase 3 Randomized Trial of Concurrent Cisplatin & Radiotherapy With Or Without ONCOVEXGM-CSF In Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck

Inclusion Criteria:

1. Male or female ≥ 18 years

2. ECOG Performance Status ≤ 1

3. Histological evidence (from the primary lesion and/or lymph nodes) of squamous cell
carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx

4. Stage III or IV disease (T2N2-3M0, T3-4N1-3M0)

5. No evidence of distant metastases by CT or PET/CT scan

6. Life expectancy > 4 months

7. Neutrophil count ≥ 2,000/mm^3

8. Platelet count ≥ 100,000/mm^3

9. Hemoglobin ≥ 10 g/dL

10. Bilirubin ≤ 1.5 times ULN

11. AST and ALT ≤ 2.5 times ULN

12. Alkaline phosphatase ≤ 2.5 times ULN

13. Creatinine clearance ≥ 60 mL/min

14. Female patients of child-bearing potential (i.e. not surgically sterile, or not
having spontaneous amenorrhea for at least 12 months) must agree to use an effective
form of contraception during the treatment phase of the study.

15. Male patients must agree to use a condom with spermicide or their female partner must
use an effective method of birth control.

16. Provide written informed consent in accordance with all applicable regulations and
follow the study procedures. Patients must be capable of understanding the
investigational nature, potential risks and benefits of the study.

Exclusion Criteria:

1. Prior treatment for locally advanced SCCHN (NO prior surgery for SCCHN except nodal
sampling or biopsy for study disease).

2. Patients with T1-2N1 or T1N2-3.

3. Pre-existing peripheral neuropathy ≥ Grade 2 (motor or sensory).

4. Weight loss > 20% of body weight within 3 months of screening (unless purposeful).

5. Surgery ≤ 28 days before randomization with the exception of feeding tube placement,
dental extractions, central venous catheter placement, biopsies and nodal sampling.

6. Cancer of the nasopharynx, sinus, salivary gland or skin.

7. Previous radical RT to the head and neck region, excluding superficial RT for a
non-melanomatous skin cancer.

8. Prior cancers, except: those diagnosed > 5 years ago with no evidence of disease
recurrence and clinical expectation of recurrence of less than 5%; or successfully
treated non-melanoma skin cancer; or carcinoma in situ of the cervix.

9. Significant intercurrent illness that will interfere with the chemotherapy or
radiation therapy such as HIV infection, cardiac failure, pulmonary compromise
(chronic obstructive pulmonary disease, pneumonia or respiratory decompensation)
resulting in hospitalization within 12 months of screening, or active infection.

10. Any significant cardiac disease (e.g., New York Heart Association (NYHA) Class 3 or
4; myocardial infarction within the past 6 months; unstable angina; coronary
angioplasty or coronary artery bypass graft (CABG) within the past 6 months; or
uncontrolled atrial or ventricular cardiac arrhythmias..

11. High risk for poor compliance with therapy or follow up as assessed by the

12. Active herpes labialis, other lesions due to HSV1 or dermatoses involving or within
50 cm of the lesions to be injected; active HSV1 lesions must have resolved before
OncoVEXGM-CSF is injected.

13. Prior systemic chemotherapy for any type of cancer.

14. Patients for whom radiation therapy is contraindicated.

15. Pregnant or breast-feeding female. Confirmation that women of child-bearing potential
are not pregnant. A negative serum β- human chorionic gonadotropin (β-hCG) pregnancy
test result must be obtained during the screening period.

16. Currently enrolled and receiving an investigational agent in a clinical research
study or received an investigational agent for any reason within 4 weeks prior to

17. Require intermittent or chronic treatment with an anti-herpetic drug (e.g.,
acyclovir), other than intermittent topical use.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To demonstrate a statistically significant increase in 2-year event free survival for patients treated with OncoVEX^GM-CSF as compared to patients treated with chemoradiation alone.

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Kevin Harrington, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Royal Marsden, UK


United States: Food and Drug Administration

Study ID:




Start Date:

December 2010

Completion Date:

December 2017

Related Keywords:

  • Squamous Cell Carcinoma
  • Head and Neck Cancer
  • head and neck cancer
  • squamous cell
  • Oncovex
  • chemoradiation
  • Cisplatin
  • Carcinoma
  • Carcinoma, Squamous Cell
  • Head and Neck Neoplasms



Gabrail Cancer Center Canton, Ohio  44718
Investigative Clinical Research of Indiana Indianapolis, Indiana  46254
James Graham Brown Cancer Center, University of Louisville Louisville, Kentucky  40202
VCU Massey Cancer Center Richmond, Virginia  23298
Medical Univesity of South Carolina Charleston, South Carolina  29425